74 related articles for article (PubMed ID: 14991540)
1. HMB-45, S-100, NK1/C3, and MART-1 in metastatic melanoma.
Zubovits J; Buzney E; Yu L; Duncan LM
Hum Pathol; 2004 Feb; 35(2):217-23. PubMed ID: 14991540
[TBL] [Abstract][Full Text] [Related]
2. Improved immunohistochemical evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma with 'MCW melanoma cocktail'--a mixture of monoclonal antibodies to MART-1, Melan-A, and tyrosinase.
Shidham VB; Qi D; Rao RN; Acker SM; Chang CC; Kampalath B; Dawson G; Machhi JK; Komorowski RA
BMC Cancer; 2003 May; 3():15. PubMed ID: 12735792
[TBL] [Abstract][Full Text] [Related]
3. Histopathological patterns of melanoma metastases in sentinel lymph nodes.
Murray CA; Leong WL; McCready DR; Ghazarian DM
J Clin Pathol; 2004 Jan; 57(1):64-7. PubMed ID: 14693838
[TBL] [Abstract][Full Text] [Related]
4. Photothermal multispectral image cytometry for quantitative histology of nanoparticles and micrometastasis in intact, stained and selectively burned tissues.
Nedosekin DA; Shashkov EV; Galanzha EI; Hennings L; Zharov VP
Cytometry A; 2010 Nov; 77(11):1049-58. PubMed ID: 20949577
[TBL] [Abstract][Full Text] [Related]
5. HMB-45 and Melan-A are useful in the differential diagnosis between granular cell tumor and malignant melanoma.
Gleason BC; Nascimento AF
Am J Dermatopathol; 2007 Feb; 29(1):22-7. PubMed ID: 17284958
[TBL] [Abstract][Full Text] [Related]
6. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma.
Busam KJ; Chen YT; Old LJ; Stockert E; Iversen K; Coplan KA; Rosai J; Barnhill RL; Jungbluth AA
Am J Surg Pathol; 1998 Aug; 22(8):976-82. PubMed ID: 9706977
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical characteristics of melanoma.
Ohsie SJ; Sarantopoulos GP; Cochran AJ; Binder SW
J Cutan Pathol; 2008 May; 35(5):433-44. PubMed ID: 18399807
[TBL] [Abstract][Full Text] [Related]
8. S100, HMB-45, and Melan-A negative primary melanoma.
Shinohara MM; Deubner H; Argenyi ZB
Dermatol Online J; 2009 Sep; 15(9):7. PubMed ID: 19930994
[TBL] [Abstract][Full Text] [Related]
9. HMB-45 staining in benign and malignant melanocytic lesions. A reflection of cellular activation.
Skelton HG; Smith KJ; Barrett TL; Lupton GP; Graham JH
Am J Dermatopathol; 1991 Dec; 13(6):543-50. PubMed ID: 1725245
[TBL] [Abstract][Full Text] [Related]
10. False-positive cells in sentinel lymph nodes.
Brennick JB; Yan S
Semin Diagn Pathol; 2008 May; 25(2):116-9. PubMed ID: 18697715
[TBL] [Abstract][Full Text] [Related]
11. SOX10: a useful marker for identifying metastatic melanoma in sentinel lymph nodes.
Willis BC; Johnson G; Wang J; Cohen C
Appl Immunohistochem Mol Morphol; 2015 Feb; 23(2):109-12. PubMed ID: 25356946
[TBL] [Abstract][Full Text] [Related]
12. Characterization of micrometastatic disease in melanoma sentinel lymph nodes by enhanced pathology: recommendations for standardizing pathologic analysis.
Spanknebel K; Coit DG; Bieligk SC; Gonen M; Rosai J; Klimstra DS
Am J Surg Pathol; 2005 Mar; 29(3):305-17. PubMed ID: 15725798
[TBL] [Abstract][Full Text] [Related]
13. The pattern of HMB-45 antibody staining in compound Spitz nevi.
Bergman R; Dromi R; Trau H; Cohen I; Lichtig C
Am J Dermatopathol; 1995 Dec; 17(6):542-6. PubMed ID: 8599465
[TBL] [Abstract][Full Text] [Related]
14. Comparison of immunohistochemical staining of the novel antibody melan-A with S100 protein and HMB-45 in malignant melanoma and melanoma variants.
Blessing K; Sanders DS; Grant JJ
Histopathology; 1998 Feb; 32(2):139-46. PubMed ID: 9543670
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous Melanoma: A Review of Multifactorial Pathogenesis, Immunohistochemistry, and Emerging Biomarkers for Early Detection and Management.
Gosman LM; Țăpoi DA; Costache M
Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958863
[TBL] [Abstract][Full Text] [Related]
16. Primary malignant melanoma of the gall bladder masquerading as xanthogranulomatous cholecystitis.
Kumar K; Zaidi A; Husain N; Chandra A
BMJ Case Rep; 2023 Sep; 16(9):. PubMed ID: 37734863
[TBL] [Abstract][Full Text] [Related]
17. Identification of TUBB4A as a Prognostic Biomarker of Melanoma by Transcriptomic Data and
Zhang J; Zhang Y; Liu J; Luo J; Yun Y; Cao Y
Technol Cancer Res Treat; 2023; 22():15330338231184842. PubMed ID: 37439014
[No Abstract] [Full Text] [Related]
18. Imaging Mass Spectrometry for the Classification of Melanoma Based on
Casadonte R; Kriegsmann M; Kriegsmann K; Streit H; Meliß RR; Müller CSL; Kriegsmann J
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982192
[TBL] [Abstract][Full Text] [Related]
19. Locally advanced choroidal melanoma with favorable molecular prognosis - case report.
Bălăşoiu AT; Ştefănescu-Dima AŞ; Bălăşoiu M; Ciurea RN; Muraru A; Dan AO; Simionescu CE
Rom J Morphol Embryol; 2022; 63(4):645-652. PubMed ID: 36808200
[TBL] [Abstract][Full Text] [Related]
20. S-100-negative, GNA11 mutation-positive intramedullary meningeal melanocytoma of the thoracic spine: A radiographic challenge and histologic anomaly.
Flores A; Gadot R; Noorbhai I; Hall H; Heck KA; Raper DMS; Xu D; Karas P; Mandel JJ; Ropper AE
Surg Neurol Int; 2021; 12():315. PubMed ID: 34345456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
